Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M

Aug. 09, 2022 4:12 PM ETOncternal Therapeutics, Inc. (ONCT)By: Manshi Mamtora, CFA
  • Oncternal Therapeutics press release (NASDAQ:ONCT): Q2 GAAP EPS of -$0.23 beats by $0.02.
  • Revenue of $0.2M (-77.3% Y/Y) misses by $0.26M.
  • Extended cash runway guidance to fund operations into the first half of 2024 with $78.9 million in cash and cash equivalents and no debt as of June 30, 2022

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.